Maze Therapeutics在1.5亿美元的股票发行上上涨

2025-09-11 19:45

Maze Therapeutics (NASDAQ:MAZE) shares rose over 45% premarket on Thursday after the biopharmaceutical company announced an oversubscribed private placement of its securities to raise gross proceeds of approximately $150.0 million.
The offering includes 4,000,002 shares at $16.25 each, a premium to the last closing price. In lieu of common stock, certain investors purchased 5,231,090 pre-funded warrants at a purchase price of $16.249 per pre-funded warrant.
The offering is expected to close on September 12, 2025, pending customary conditions.
Maze will use the proceeds, along with existing cash, to advance its drug pipeline, including the development of MZE829 in patients with APOL1-mediated kidney disease, MZE782 in both phenylketonuria and chronic kidney disease, as well as to support research, its Compass platform, and general corporate purposes.
Source: Press Release

More on Maze Therapeutics